Patients who received PrimeC reportedly saw significant impact to the disease’s progression. NeuroSense announced further data from its PARADIGM Phase 2b study. 1 The new data was derived from a ...
Demonstrating clinical benefit is the ultimate gateway to smoother patient access. When health plan and pharmacy benefit manager (PBM) clinical decision-makers review a Phase II or Phase III product ...
75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 ...
NEW YORK, July 31, 2025 /PRNewswire/ -- Radella Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing innovative therapies for cardiometabolic disorders, today announced that its ...
Basel, April 15, 2024 – Novartis today presented results from a pre-specified interim analysis of the Phase III APPLAUSE-IgAN study of Fabhalta ® (iptacopan), an investigational Factor B inhibitor of ...
The MarketWatch News Department was not involved in the creation of this content. -- Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across ...
This guidance note discusses how to report statistics and data, while avoiding some of the pitfalls. Advice in assessing the creditability of data-based stories; statistical checking or how to report ...
There are many different approaches for assessing process parameter criticality, and assessing which process parameters have a significant impact on critical quality attributes (CQAs) is a particular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback